Pharmacy & Therapeutics - March 2009 - (Page 133) IMPORTANT CORRECTION OF DRUG INFORMATION ABOUT BYSTOLIC® (NEBIVOLOL) TABLETS An advertisement in professional journal publications for Bystolic® (nebivolol) tablets for the treatment of hypertension was the subject of a Warning Letter issued by the U.S. Food and Drug Administration (FDA) in August 2008. Forest would like to take this opportunity to clarify the content of this advertisement. Indications and Usage Bystolic is indicated for the treatment of hypertension. Bystolic may be used alone or in combination with other antihypertensive agents. Unsubstantiated Superiority and Mechanism of Action Claims The FDA objected to claims that Bystolic was a novel and next generation beta blocker with a unique mechanism of action including cardioselective beta blockade and vasodilation. The FDA stated that these claims were misleading because they suggested that Bystolic is different from and superior to other -adrenergic receptor blocking agents in the treatment of hypertension, when these implications have not been demonstrated by substantial evidence or substantial clinical experience. In extensive metabolizers (most of the population) and at doses ≤10 mg, Bystolic is preferentially 1 selective. The FDA also stated that the presentation of the mechanism of action implied that it had been established, when the package insert states that the mechanism of action of the antihypertensive response of Bystolic has not been definitively established. Omission and Minimization of Risk Information The FDA stated that the advertisement did not disclose the following important safety information, which is contained in Bystolic’s full Prescribing Information: Warning: In patients who have compensated congestive heart failure, Bystolic should be administered cautiously. If heart failure worsens, discontinuation of Bystolic should be considered. Precautions: CYP2D6 Inhibitors: Use caution when Bystolic is co-administered with CYP2D6 inhibitors (quinidine, propafenone, fluoxetine, paroxetine, etc). Drug interactions: Drugs that inhibit CYP2D6 can be expected to increase plasma levels of nebivolol. When Bystolic is coadministered with an inhibitor or an inducer of this enzyme, patients should be closely monitored and the nebivolol dose adjusted according to blood pressure response. Fluoxetine, a CYP2D6 inhibitor, administered at 20 mg per day for 21 days prior to a single 10 mg dose of nebivolol to 10 healthy adults, led to an 8-fold increase in the AUC and 3-fold increase in Cmax for d-nebivolol. The FDA objected to the claim, “Favorable tolerability profile with a low incidence of beta blocker-related side effects.” The FDA determined that this claim implied that the tolerability profile of Bystolic is better than the tolerability profile of other -adrenergic receptor blocking agents, when this has not been demonstrated by substantial evidence or substantial clinical experience. The FDA also objected to the claim, “Favorable tolerability profile,” stating that it minimized the risks associated with Bystolic. Unsubstantiated Efficacy Claims The FDA objected to the claim, “Efficacy demonstrated across a broad range of patients.” The FDA stated that the cited claim implied that efficacy was demonstrated within each subgroup (obese, poor metabolizers, and diabetic) presented in conjunction with this claim, when this has not been supported by substantial evidence or substantial clinical experience. None of the efficacy trials for Bystolic were specifically designed to evaluate effectiveness in patients who were obese, poor metabolizers, or diabetic. The FDA is not aware of any studies with Bystolic demonstrating efficacy in the above referenced subgroups. Effectiveness was established in black hypertensive patients and was similar in subgroups analyzed by age and sex. Important Safety Information Patients being treated with Bystolic should be advised against abrupt discontinuation of therapy. Severe exacerbation of angina and the occurrence of myocardial infarction and ventricular arrhythmias have been reported following the abrupt cessation of therapy with beta blockers. When discontinuation is planned, the dosage should be reduced gradually over a 1- to 2-week period and the patient carefully monitored. Bystolic is contraindicated in severe bradycardia, heart block greater than first degree, cardiogenic shock, decompensated cardiac failure, sick sinus syndrome (unless a permanent pacemaker is in place), severe hepatic impairment (Child-Pugh >B), and in patients who are hypersensitive to any component of this product. Bystolic should be used with caution in patients with peripheral vascular disease, thyrotoxicosis, in patients treated concomitantly with beta blockers and calcium channel blockers of the verapamil and diltiazem type (ECG and blood pressure should be monitored), severe renal impairment, and any degree of hepatic impairment or in patients undergoing major surgery. In patients who have compensated congestive heart failure, Bystolic should be administered cautiously. If heart failure worsens, discontinuation of Bystolic should be considered. Caution should also be used in diabetic patients as beta blockers may mask some of the manifestations of hypoglycemia, particularly tachycardia. When Bystolic is administered with CYP2D6 inhibitors such as fluoxetine, significant increases in d-nebivolol may be observed (ie, an 8-fold increase in AUC). In general, patients with bronchospastic disease should not receive beta blockers. Bystolic should not be combined with other beta blockers. The most common adverse events with Bystolic versus placebo (approximately ≥1% and greater than placebo) were headache, fatigue, dizziness, diarrhea, nausea, insomnia, chest pain, bradycardia, dyspnea, rash, and peripheral edema. Please see the accompanying brief summary of Prescribing Information for full risk information. ©2008 Forest Laboratories, Inc. 44-1014486 11/08
For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.